Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p

Fig. 5

Expression of miR-561, miR-616 and miR-767-5p after transfection. At 72 h after transfection in RPMI8226 cells, miR-561 expression was reduced in SMARCA5 (+) group compared with Control (+) group but similar in SMARCA5 (−) group compared with Control (−) group (a). No difference in expression of miR-616 was observed between SMARCA5 (+) and Control (+) groups, or between SMARCA5 (−) and Control (−) groups (b). As for miR-767-5p, its expression was reduced in SMARCA5 (+) group compared with NC (+) group but raised in SMARCA5 (−) group compared with Control (−) group. Comparisons of miRNA expressions were performed using t test and P < 0.05 was considered significant. **P < 0.01, ***P < 0.001, NS, non-significant. Control (+), blank overexpression; SMARCA5 (+), Circ-SMARCA5 overexpression; Control (−), blank shRNA; SMARCA5 (−), Circ-SMARCA5 shRNA; miR, micro RNA

Back to article page